Lithium chloride cas no:7447-41-8

NameLithium chloride
CAS7447-41-8
SynonymsLithium chloride anhydrous; Lithium Ion standard solution Fluka; Lithium chloride solution; Lithium chloride, Molecular Biology Grade; Lithium Chloride, MB Grade (1.05673)
EINECS(EC#)231-212-3
Molecular FormulaLiCl
Molecular Weight42.39

Appearancewhite odourless solid
refractive indexn20/D 1.381
storage temp2-8°C
Sensitive Hygroscopic

Hazardclass8

Hazard Xn:Harmful
Risk R22;R36/38
Safety

Hazard Codes of Lithium chloride (CAS NO.7447-41-8):?F,Xn,C,Xi
Risk Statements: 11-36/37/38-35-10-19-63-20/21/22?
R11: Highly flammable.?
R36/37/38: Irritating to eyes, respiratory system and skin.?
R35: Causes severe burns.?
R10: Flammable.?
R19: May form explosive peroxides.?
R63: Possible risk of harm to the unborn child.?
R20/21/22: Harmful by inhalation, in contact with skin and if swallowed.
Safety Statements: 26-36/37/39-16-45-33-29-22?
S26: In case of contact with eyes, rinse immediately with plenty of water and seek medical advice.?
S36/37/39: Wear suitable protective clothing, gloves and eye/face protection.?
S16: Keep away from sources of ignition.?
S45: In case of accident or if you feel unwell, seek medical advice immediately (show the label whenever possible.)?
S33: Take precautionary measures against static discharges.?
S29: Do not empty into drains.?
S22: Do not breathe dust.
RIDADR: UN 2789 8/PG 2
WGK Germany: 1
RTECS: OJ5950000
F: 3-10
HazardClass: 8
PackingGroup: III
HS Code 28273980
Human poison by ingestion. Experimental poison by intravenous and intracerebral routes. Moderately toxic by subcutaneous and intraperitoneal routes. Experimental teratogenic and reproductive effects. Human systemic effects by ingestion: somnolence, tremors, nausea or vomiting. An eye and severe skin irritant. Human mutation data reported. Questionable carcinogen with experimental neoplastigenic data. This material has been recommended and used as a substitute for sodium chloride in “salt-free” diets, but cases have been reported in which the ingestion of lithium chloride has produced dizziness, ringing in the ears, visual disturbances, tremors, and mental confusion. In most cases, the symptoms disappeared when use was discontinued. Prolonged absorption may cause disturbed electrolyte balance, impaired renal function. Reaction is violent with BrF₃. When heated to decomposition it emits toxic fumes of Cl^?. Used for dehumidification in the air conditioning industry. Also used to obtain lithium metal. See also LITHIUM COMPOUNDS.

HS Code 28273980

Organism	Test Type	Route	Reported Dose (Normalized Dose)	Effect	Source
bird - wild	LD50	oral	422mg/kg (422mg/kg)	?	Archives of Environmental Contamination and Toxicology. Vol. 12, Pg. 355, 1983.
cat	LD50	intraperitoneal	492mg/kg (492mg/kg)	?	Russian Pharmacology and Toxicology Vol. 42, Pg. 9, 1979.
cat	LDLo	subcutaneous	450mg/kg (450mg/kg)	?	Environmental Quality and Safety, Supplement. Vol. 1, Pg. 1, 1975.
dog	LDLo	intravenous	500mg/kg (500mg/kg)	BEHAVIORAL: FOOD INTAKE (ANIMAL) GASTROINTESTINAL: CHANGES IN STRUCTURE OR FUNCTION OF SALIVARY GLANDS MUSCULOSKELETAL: OTHER CHANGES	Journal of Pharmacology and Experimental Therapeutics. Vol. 100, Pg. 429, 1950.
frog	LDLo	subcutaneous	885mg/kg (885mg/kg)	?	"Abdernalden's Handbuch der Biologischen Arbeitsmethoden." Vol. 4, Pg. 1289, 1935.
guinea pig	LD50	intraperitoneal	624mg/kg (624mg/kg)	?	"Spravochnik po Toksikologii i Gigienicheskim Normativam Vol. -, Pg. 157, 1999.
guinea pig	LDLo	subcutaneous	620mg/kg (620mg/kg)	?	Environmental Quality and Safety, Supplement. Vol. 1, Pg. 1, 1975.
human	LDLo	oral	200mg/kg/3D (200mg/kg)	BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) BEHAVIORAL: MUSCLE CONTRACTION OR SPASTICITY) BEHAVIORAL: MUSCLE WEAKNESS	JAMA, Journal of the American Medical Association. Vol. 139, Pg. 688, 1949.
human	TDLo	oral	243mg/kg/13D (243mg/kg)	BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) BEHAVIORAL: TREMOR GASTROINTESTINAL: NAUSEA OR VOMITING	JAMA, Journal of the American Medical Association. Vol. 139, Pg. 688, 1949.
mouse	LD50	intracrebral	14040ug/kg (14.04mg/kg)	SENSE ORGANS AND SPECIAL SENSES: PTOSIS: EYE BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)	Nippon Yakurigaku Zasshi. Japanese Journal of Pharmacology. Vol. 69, Pg. 75, 1973.
mouse	LD50	intraperitoneal	600mg/kg (600mg/kg)	?	Journal of Thermal Biology. Vol. 6, Pg. 87, 1981.
mouse	LD50	intravenous	363mg/kg (363mg/kg)	BRAIN AND COVERINGS: RECORDINGS FROM SPECIFIC AREAS OF CNS BEHAVIORAL: ANTIPSYCHOTIC	Oyo Yakuri. Pharmacometrics. Vol. 7, Pg. 413, 1973.
mouse	LD50	oral	1165mg/kg (1165mg/kg)	?	Russian Pharmacology and Toxicology Vol. 33, Pg. 266, 1970.
mouse	LD50	subcutaneous	738mg/kg (738mg/kg)	BEHAVIORAL: TREMOR MUSCULOSKELETAL: OTHER CHANGES	Acta Pharmacologica et Toxicologica. Vol. 43, Pg. 51, 1978.
pigeon	LDLo	subcutaneous	513mg/kg (513mg/kg)	?	"Abdernalden's Handbuch der Biologischen Arbeitsmethoden." Vol. 4, Pg. 1289, 1935.
quail	LD50	oral	422mg/kg (422mg/kg)	?	Archives of Environmental Contamination and Toxicology. Vol. 12, Pg. 355, 1983.
rabbit	LD50	oral	800mg/kg (800mg/kg)	?	Farmakologiya i Toksikologiya Vol. 39, Pg. 53, 1976.
rabbit	LDLo	subcutaneous	531mg/kg (531mg/kg)	?	Environmental Quality and Safety, Supplement. Vol. 1, Pg. 1, 1975.
rat	LD50	intracrebral	4800ug/kg (4.8mg/kg)	BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX) BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)	Polish Journal of Pharmacology and Pharmacy. Vol. 26, Pg. 399, 1974.
rat	LD50	intraperitoneal	514mg/kg (514mg/kg)	?	Personal Communication from K.P. Petersen, DAK Labs., 59 Lergravsvej, DK-2300, Copenhagen, Demark, Dec. 22, 1977Vol. 22DEC1977,
rat	LD50	intratracheal	205mg/kg (205mg/kg)	?	"Spravochnik po Toksikologii i Gigienicheskim Normativam Vol. -, Pg. 157, 1999.
rat	LD50	oral	526mg/kg (526mg/kg)	?	Acta Pharmacologica et Toxicologica. Vol. 47, Pg. 351, 1980.
rat	LD50	subcutaneous	499mg/kg (499mg/kg)	?	Personal Communication from K.P. Petersen, DAK Labs., 59 Lergravsvej, DK-2300, Copenhagen, Demark, Dec. 22, 1977Vol. 22DEC1977,